Effects ofSLC22A1Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance-Reference-Cited by-同舟云学术

Effects ofSLC22A1Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance

Published:2016-08-23 Issue:2 Volume:57 Page:219-229
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Sam Wai Johnn¹,Roza Orsolya²³,Hon Yuen Yi¹⁴,Alfaro Raul M.¹,Calis Karim A.¹⁵,Reynolds James C.⁶,Yanovski Jack A.²

Affiliation:

1. Clinical Pharmacokinetics Research Laboratory; Clinical Center Pharmacy Department; National Institutes of Health; Bethesda MD USA

2. Section on Growth and Obesity, Program in Developmental Endocrinology and Genetics; Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health; Bethesda MD USA

3. Institute of Pharmacognosy; University of Szeged; Szeged Hungary

4. Office of Clinical Pharmacology; Office of Translational Sciences; Center for Drug Evaluation and Research; Food and Drug Administration; Silver Spring MD USA

5. Office of the Clinical Director; Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health; Bethesda MD USA

6. Nuclear Medicine Division; Radiology and Imaging Sciences, Clinical Center; National Institutes of Health; Bethesda MD USA

Funder

National Institute of Child Health and Human Development

National Institute on Minority Health and Health Disparities

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference48 articles.

1. Special Focus II: The Size and Risks of the International Epidemic of Child Obesity

2. Worldwide trends in childhood overweight and obesity;Wang;Int J Pediatr Obes,2006

3. Obesity in children and young people: a crisis in public health;Lobstein;Obes Rev,2004